A Phase 3 trial of a small molecule drug designed to treat patients with metastatic non-small cell lung cancer failed to meet its primary endpoint of overall survival, the sponsor Ipsen SA announced on 8 December. Cabozantinib was being investigated in 366 patients with both squamous and non-squamous non-small cell lung cancer whose disease had progressed after treatment with a checkpoint inhibitor and chemotherapy.
